Stephen Jackson is a Founder and Chief Scientific Officer of Neurotherapeutics Ltd, Professor of Cognitive Neuroscience at the University of Nottingham and has over 30 years research experience investigating human sensorimotor function in health and disorder.
He is the first recipient of the ‘Dirk Bakker Visiting Professorship’ awarded by the Stichting Neuropsychologie Nederland (Dutch Neuropsychology Society) and is currently Chair of the Scientific Advisory Board of the Federation of European Societies for Neuropsychology (FESN). Stephen has previously served as President of the British Association for Cognitive Neuroscience (BACN), Director of the University of Nottingham’s Institute of Neuroscience and from 2007–2012 he chaired a European Research Network Programme (RNP) on ‘Human Sensorimotor Function in Health and Disease’.
His research has been funded by many funding organisations including: the Wellcome Trust; NIHR; MRC; BBSRC; BUPA Foundation; Tourette Association of America; and Tourettes Action and he has provided scientific advice and guidance to a wide range of governmental, industrial, academic and charitable organisations including the UK Ministry of Defence, Unilever, the MRC and Wellcome Trust. From 2009 – 2012 Stephen was appointed ‘Distinguished Overseas Professor’ at Korea University, South Korea. His role was to assist in establishing a new centre for research and teaching excellence in ‘Brain and Cognitive Engineering’ at Korea University and to lead a research team investigating Brain Plasticity Mechanisms.
Georgina Jackson is a Founder, Director and Senior Science Officer of Neurotherapeutics Ltd and Emeritus Professor of Cognitive Neuropsychology, School of Medicine, University of Nottingham.
She has an extensive track-record of externally funded research investigating the brain mechanisms underlying goal-directed behaviour in health and disorder. Her work has focused on understanding the development of cognitive control processes (often referred to as executive function) during childhood and adolescence and how these processes are affected by neurodevelopmental conditions such as Tourette Syndrome (TS). Over the past ten years she has focused on non-pharmacological treatments for TS publishing on the therapeutic impacts of exercise and more recently the use of median nerve stimulation.
She has been funded by the Wellcome Trust, MRC, BBSRC, ESRC, NIHR amongst others and has been actively involved in Tourette Syndrome research for over twenty years. In 2009 she was commissioned by UK charity Tourettes Action, with funding from the Big-Lottery Fund, to examine the psycho-social experiences of young people with Tourette Syndrome and she co-authored a Healthcare Technology Association report on the clinical effectiveness and patients perspectives on treatments for TS. Georgina has previously served as General Secretary of the British Neuropsychological Society and a member of the Board of Trustees of Tourettes Action (2014-2023).
Barbara carried out the research studies leading to the technology that Neurotherapeutics Ltd is developing into a wearable medical device aimed at controlling symptoms of Tourette Syndrome.
With over seven years of focused research on Tourette Syndrome, Barbara has worked closely with those affected by the condition. She oversees all research activities with the goal of enhancing the quality of life for individuals with Tourette Syndrome.
Ian is currently serving as Chair of the Board and Non-Executive Director for Neurotherapeutics Ltd. Ian was involved as an Investor Director during the early company formation, an engineer by background bringing over 35 years’ experience of working with new technologies and the Life Sciences.
Previously, Ian was the CEO of McLaren Applied Technologies and former Senior Partner at PA Consulting Group where he delivered value to many of the global corporations and investors across the Life Sciences.
Georgina has over 35 years of research experience and twenty years investigating Tourette Syndrome.
Her current work focuses on support the development of safe and effective therapies for home use in brain health conditions which are informed by patient experience.
With over 7 years of focused research on Tourette Syndrome, Barbara has worked closely with those affected by the condition. She oversees all research activities with the goal of enhancing the quality of life for individuals with Tourette Syndrome.
James is a member of the team at Nottingham Technology Ventures Ltd, the subsidiary company of the University of Nottingham responsible for the formation of and investment in spin out companies.
A life scientist by training he has over 20 years of experience working both in industry and university technology transfer including holding a number of board positions.
Paul has over 30 years of experience in the medical device and pharmaceutical field, working previously for Baxter Healthcare and lately through his own consultancy working with startups and established businesses.
Paul helped the University of Nottingham to spin out Neurotherapeutics Ltd and has lead the company as CEO since February 2021.
Andrew holds a PhD in Molecular Physics and has over 15 years’ experience in leading early stage venture capital backed medical device and biotech companies. Andrew joined the board in early 2024.
Dr David Moser is an experienced engineer in the areas of Robotics and Medical devices. He brings over 17 years of experience developing wearable assistive technologies and medical devices.
He is former Director of Research and Technology at Blatchford where he led the development of some of the world’s most advanced prosthetics and a succession of award-winning products including the RAEng MacRobert Award finalist in 2010, winner in 2016 and the US Medical Device excellence award in 2017.
He is a Chartered Engineer and a Visiting Professor at the University of Southampton. He holds over 25 patents and has published extensively in the areas, of prosthetics, body interface technologies, Robotics, physical rehabilitation, and digital health. He is responsible for technology and new product development.
Claire has over 20 years of experience in quality management practices, ISO certification and regulatory affairs predominantly within the medical device and pharmaceutical industries.
She is responsible for our Quality Management System, ISO certification, Data Protection and Health, Safety and Wellbeing.
Ciara was involved in the Neurotherapeutics Ltd clinical trial in 2022 as a psychology assistant following her Masters in Developmental Psychology at the University of Nottingham. Ciara works alongside participants with Tourette Syndrome to gain valuable feedback about their experience and she is involved in collecting and analysing data from the clinical trial and subsequent research studies.
Ciara is conducting research on behalf of the company to aid the further development of a wearable medical device and an app to monitor symptoms.
Kyran has over 6 years of experience in office management practices and provides an efficient and high standard of support to the entire team.
Company number: 13198315
Registered Office:
The Ingenuity Centre
University Of Nottingham Innovation Park
Triumph Road
Nottingham
England
NG7 2TU
Neupulse and Neutrack are registered trade marks of Neurotherapeutics Ltd
